CAC 40
7 628,57 -42,77 (-0,56 %) Euro Stoxx 50
4 907,30 -40,43 (-0,82 %) Dow Jones
39 150,33 +15,57 (+0,04 %) EUR/USD
1,0697 -0,0009 (-0,09 %) Gold future
2 334,70 -34,30 (-1,45 %) Bitcoin EUR
60 260,88 +161,99 (+0,27 %)
GSK plc (GS71.F)
GSK plc
980 Great West Road
Middlesex
Brentford TW8 9GS
United Kingdom
44 20 8047 5000
https://www.gsk.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 70 212
Description
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Gouvernance d’entreprise
L’ISS Governance QualityScore de GSK plc en date du 1 juin 2024 est 9. Les scores principaux sont Audit : 10; Société : 5; Droits des actionnaires : 1; Compensation : 9.
